Last reviewed · How we verify
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine is a Biologic drug developed by Duke University. It is currently FDA-approved. Also known as: Flu vaccine, 2016-2017 Flu vaccine.
The 2016-2017 Quadrivalent Inactivated Influenza Vaccine, developed by Duke University, is currently marketed but lacks detailed revenue figures. A key strength is the patent protection extending to 2028, which helps maintain market exclusivity. The primary risk is the lack of specified competitors and trial results, which could impact market positioning and regulatory confidence.
At a glance
| Generic name | 2016-2017 Quadrivalent Inactivated Influenza Vaccine |
|---|---|
| Also known as | Flu vaccine, 2016-2017 Flu vaccine |
| Sponsor | Duke University |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women (PHASE4)
- Study of Biomarkers of Immune Activation Associated with Symptoms and Immune Responses After Influenza Vaccination in Adults (PHASE4)
- Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in India (PHASE3)
- Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children (PHASE4)
- Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations (PHASE4)
- Age and Response to Flu Vaccines (PHASE4)
- Immunogenicity and Safety Evaluation of QIS in Healthy Subjects (PHASE3)
- A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 2016-2017 Quadrivalent Inactivated Influenza Vaccine CI brief — competitive landscape report
- 2016-2017 Quadrivalent Inactivated Influenza Vaccine updates RSS · CI watch RSS
- Duke University portfolio CI
Frequently asked questions about 2016-2017 Quadrivalent Inactivated Influenza Vaccine
What is 2016-2017 Quadrivalent Inactivated Influenza Vaccine?
Who makes 2016-2017 Quadrivalent Inactivated Influenza Vaccine?
Is 2016-2017 Quadrivalent Inactivated Influenza Vaccine also known as anything else?
What development phase is 2016-2017 Quadrivalent Inactivated Influenza Vaccine in?
Related
- Manufacturer: Duke University — full pipeline
- Also known as: Flu vaccine, 2016-2017 Flu vaccine
- Compare: 2016-2017 Quadrivalent Inactivated Influenza Vaccine vs similar drugs
- Pricing: 2016-2017 Quadrivalent Inactivated Influenza Vaccine cost, discount & access